Looking Into Eli Lilly's Recent Short Interest
Rhythm Pharma Draws Bullish View at JMP on Opportunity in Rare Genetic Obesities
Unpacking the Latest Options Trading Trends in Eli Lilly
Pfizer Unusual Options Activity
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
Beyond The Numbers: 13 Analysts Discuss Pfizer Stock
CG Oncology Surges 7%; Seen Benefitting From J&J Bladder Cancer Asset Data
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Pfizer Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Eli Lilly, Maintains $885 Price Target
Eli Lilly Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target
Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Bristol-Myers Squibb Analyst Ratings
DeSantis Administration Cautions Against Pfizer, Moderna MRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Moderna Was Most Shorted S&P 500 Healthcare Stock in August for Second Consecutive Month
Johnson & Johnson Analyst Ratings
Pfizer Presents Positive Data From Phase 2 Study of Ponsegromab in Patients With Cancer Cachexia
Reported Saturday, Pfizer's BRAFTOVI + MEKTOVI Shows Long-Term Efficacy In BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer Patients After Three-Year Follow-Up
Reported Saturday, Johnson & Johnson Shares New Data on RYBREVANT in Metastatic Colorectal Cancer at ESMO Congress